Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alexion Pharmaceuticals, Inc.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant weighs ≥ 30 kg
Planned non-emergent sternotomy with CPB procedure for the following surgeries:
Multi-vessel CABG
Valve replacement or repair; ascending aorta surgery permitted if combined with aortic valve replacement/repair
Combined CABG and valve surgery; inclusion of single-vessel CABG when combined with valve replacement/repair is permitted
Known CKD for at least 90 days (CKD Stage 3A, 3B, or 4)
You may not be if
Emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the investigator.
Single-vessel CABG without valve surgery is planned.
Off-pump surgery is planned (eg, surgery without CPB).
Recipient of a solid organ or bone marrow transplantation.
Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization.
Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.
History of unexplained, recurrent infection.
Any use of KRT or presence of AKI within 30 days of randomization
Use of any complement inhibitors, or plasmapheresis or plasma exchange within the year prior to Screening, or planned use during the course of the study.
Participant is not willing to be vaccinated against N meningitidis or is unwilling to receive prophylactic treatment with appropriate antibiotics , if needed
History of or unresolved N meningitidis infection.
